Danaher Corporation with ticker code (DHR) have now 20 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 282.93 and 193.34 suggesting an average Analsyt target price of $246.83. Given that the stocks previous close was at $196.84 this would indicate that there is a potential upside of 25.4%. The 50 day MA is $219.79 and the 200 moving average now moves to $219.60. The company has a market cap of 142.35B. The current share price for the company is: 192.65 USD
The potential market cap would be $178,506,950,081 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 24.26, revenue per share of 40.29 and a 5.21% return on assets.
Danaher Corporation designs, manufactures and markets professional, medical, industrial, and commercial products and services. The Company’s segments include Biotechnology, which includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables and services; Life Sciences segment, which offers a range of instruments and consumables that are primarily used by customers to study the basic building blocks of life, including genes, proteins, metabolites, and cells, to understand the causes of disease, identify new therapies, and test and manufacture new drugs and vaccines; Diagnostics segment that offers clinical instruments, reagents, consumables, software, and services that hospitals, physicians’ offices, reference laboratories, and other critical care settings use to diagnose disease, and Environmental & Applied Solutions segment, which offers products and services that help protect precious resources and keep global food and water supplies safe.
